retrospect diagnost servic growth stock confer
follow william blair annual growth stock confer follow note provid
recap takeaway thought space gener
present compani list alphabet order
laboratori corpor america hold lh outperform
laboratori corpor america hold
pleas refer import disclosur page analyst certif page
william blair affili seek busi compani cover research report
result investor awar firm may conflict interest could affect object
report report intend provid person invest advic opinion recommend
herein take account individu client circumst object need intend
recommend particular secur financi instrument strategi particular client recipi
report must make independ decis regard secur financi instrument mention
retrospect confer takeaway diagnost servic
number diagnost servic compani attend confer includ foundat medicin labcorp
myriad high-level takeaway certainli sentiment appear
shift space wholew believ part driven recent ncd publish medicar cover next-
gener sequenc assay companion diagnost well burgeon pharma pipelin target drug
innov part platform vendor facilit cost-effect multiplex chang game enabl
multigen drug target use pan-canc biomark requir complex test methodolog tmb
addit part neg term impact price implement pama provid much need
visibl price least three-year period tumultu year
term stock
clearli foundat medicin gener buzz given recent roch rhhbi announc
even prior announc foundat medicin session well attend note entitl
roch acquir fmi whop ev/sal great space highlight underappreci
opportun thought transact sum view transact posit space
wholea valid valu genom test seemingli recognit pharma import
neogenom one top long-term idea given view stori potenti inflect pointwhat
perhap underappreci lead pure-play oncolog test compani see
neogenom clear potenti beneficiari recent medicar ncd given compani technic
capabl combin commerci infrastructur balanc sheet pursu broad fda approv
sequencing-bas assay expect comprehens genom profil market remain rel central
among player given complex perform test need outcom data moreov
compani pharma busi small put strong robust perform recent partnership
could also drive upsid number time
also one top small/micro-cap idea believ compani abil monet machin
learn platform build multipl assay time biobank thousand thyroid lung
cancer sampl underappreci make meaning progress afirma assay thyroid cancer
compani commerci test lung diseas provid addit leg stori percepta lung
cancer medicar coverag begun contribut statement provid avenu growth
acceleration/revenu upsid rel estim
see myriad near-term catalyst-driven opportun given potenti number data point around
compani genesight assay public rct impact data well unitedhealthcar cost
effect studi potenti privat payer reimburs given compani alreadi built
commerci infrastructur pipelin test new reimburs coverag could drive meaning earn
leverag expect compani continu use balanc sheet/cash flow consolid space
impress progress made expand genom reach carrier screen prenat
test exom sequenc exampl fan price disrupt model also acknowledg
compani build meaning scale drive cost effect test
final believ secular trend labcorp quest favor industri face reimburs pressur
result pama stronger player abl consolid market see opportun share shift
volum lower-cost independ lab region lab share gain drive higher histor growth lab
attend compani troy cox ceo jason ryan cfo jeff palmer corpor control
medicar ncd key focu discuss recent medicar ncd impact compani late may
foundat medicin announc receiv statu foundationon cdx initi data
collect period begin juli end march part pama price test determin
base median privat payer rate receiv compani collect period
collect period test reimburs howev median rate higher
foundat medicin refund amount expect ncd begin larger
impact back half interpret manag commentari compani expect
market competit competitor opt pursu pma design given amount decentr
foundat act foundat medicin also recent receiv breakthrough devic design expand
version liquid biopsi assay foundationact fda late april expand version includ analysi
gene well microsatellit instabl blood tumor mutat burden btmb use circul
cell-fre dna cfdna percept compani continu view liquid biopsi assay appropri
altern tissu availableand therefor least yet replac tissue-bas assay
enabl evalu genes/mark howev discuss potenti long-term use
liquid biopsi assay monitor purpos yet compani defin address market
million patient unit state could sizabl upsid materi
reimburs get read commerci payer coverag medicar advantag plan
run commerci player statutorili oblig cover foundationon cdx new ncd iron
medicar advantag plan make lion share privat payer rate calcul
initi period pama
roch clearli bigger news merger roch announc tuesday morn june necessarili
surpris given roch exist invest compani certainli repres sizabl multipl
attend compani sean georg ceo shelli guyer cfo
menu expans stood us transit compani made hereditari cancer focu
much broader test menuinclud introduct exom sequenc recent move
preimplant genet carrier screen prenat diagnosi acquisit combimatrix
start genet addit also recent partner kew inc develop comprehens genom
profilingmark move somat mutat detect sinc kew relationship partnership versu
acquisit unclear whether kew opt pursu fda approv comprehens genom profil
reimburs stock seen volatil recent quarter compani face variou collect
challeng includ broader aim portal implement back meaning movement
in-network contract compani seen past coupl year insourc bill oper
roughli nine month ago begun see benefitwith cash collect million test
biopharma addit manag highlight compani build network partnership biopharma
compani well advocaci organ agreement benefici strateg perspect
manag believ start paradigm shift use genet test busi perspect
agreement provid compani nice stream consist volum revenu
brca reimburs chang final term new inform compani concurr file last
tuesday provid updat medicar payment second quarter compani notifi
medicar approv payment deletion/dupl analysi certain test code
duplication/delet alongsid code genom sequenc analysi panel includ least
gene includ atm
use bill four panel multi-canc panel common hereditari cancer
panel breast gyn gi invita breast gyn cancer guideline-bas panel invita breast gyn cancer
panel code introduc januari medicar rate set
assum could perform deletion/dupl medicar
volum believ could add approxim million revenu yearli basi base
stock thought volum growth continu impress believ updat guidanc still leav
plenti room upsid also believ becom compel stori given view
genom market central key player maintain market perform rate howev given
view larg commerci infrastructur would need support futur growth maintain
laboratori corpor america hold lh
attend compani glenn eisenberg cfo scott frommer vice presid investor relat
unitedhealthcare/aetna aet probabl surpris focu recent contract chang
especi given first time compani spoke publicli sinc announc discuss
recent note dust settl upgrad outperform believ net impact labcorp
neg given size unit busi rel aetna manag given specif also
expect price ration believ rel higher given shift unit busi exclus
nonexclus manag provid guidanc estim contract chang reduc adjust
ep
said labcorp quest discuss detail highlight value-bas arrang
within new contract ground-break rel way payer histor manag lab spend
neither compani given mani specif ultim believ new contract provid opportun
labcorp quest work respect payer reduc overal lab spend share cost save
addit given larg lab network larg major payer see potenti
player gain share region lab market roughli total
lab busi independ contract chang continu believ labcorp benefit secular
tailwind given implement pama earli larg independ lab continu benefit
hospit need lower cost rais capit view earli phase shift market share
hospit lab independ lab whether acquisit outreach lab joint ventur partnership
structur lab manag arrang
cro covanc continu put strong book-to-bil numbersat end first quarter compani
book-to-bil ratio basi adjust robust backlog convers suggest
compani abl withstand mid- high-single-digit organ growth cro segment sever
quarter addit sustain organ growth acquisit chiltern complet septemb
help broaden diversifi labcorp custom base high-grow emerg midmarket segment
late-stag clinic trial part busi oppos reli big biopharma although spring
survey biopharmaceut sponsor show covanc continu maintain lead term best
posit win earlier stage earlier stage trial repres less third total revenu
segment shift toward late stage survey show covanc well-posit top three cro
result faster backlog convers acceler revenu near term
end april labcorp sold covanc food solut million labcorp histor
acquisit compani manag continu analyz compani portfolio determin whether asset
divest food solut busi contribut roughli million revenu pro
forma basi meet manag criteria market leader compani willing divest
non-core asset even asset contribut revenu incom highlight manag optim
opportun compani within diagnost remain cro busi
gener labcorp free cash flow gener also impress given compani back within
target rang gross debt ebitda potenti signific capit return sharehold
assum compani make increment sizabl acquisit april labcorp
board director author increas compani share repurchas program total billion
current estim free cash flow billion per share basi expect compani buy back
approxim million share given substanti cash flow gener compani upsid
estim share buyback especi consid estim current includ increment
cash flow divestitur covanc food solut
attend compani bryan riggsbe cfo scott gleason vice presid investor relat
hereditari cancer hereditari cancer manag highlight compani rich databas identifi
variant enabl myriad maintain price premium add new offer riskscor test
launch oncolog prevent care market less penetr
respect leav plenti room volum growth manag go far say hereditari
busi would grow fiscal give guidanc yet given visibl price volum growth
exceed expect posit growth possibl model hereditari cancer revenu million fiscal
flat rel estim fiscal
counsyl myriad commerci stage product global total address market billion
recent acquisit counsyl give compani access reproduct test spacemanag
highlight market predict experi test volum growth next five year
acquisit creat largest genet salesforc women health tripl physician reach counsyl test
add potenti cross-sel opportun hereditari cancer view manag guidanc around
potenti accret counsyl conserv neutral fiscal ep accret fiscal ep
given includ revenu synergi deal see opportun counsyl add ep
upsid rel guidanc fiscal anoth
genesight term genesight manag reiter expect data publish end fiscal
year june addit result impact studi unitedheatlhcar cost save studi expect
publish second half calendar year interpret manag commentari compani
bullish potenti privat payer reimburs genesight particularli see public
data
revenu myriad intern expans current constrain sever countri prefer
test done domest compani work overcom obstacl establish rna kit
complex hereditari cancer test administ kit form altern viabl
rna protein express test endopredict prolari mypath melanoma vectra da mypath bipolar
profit compani well path toward goal creat million increment oper profit
save driven chang front-end laboratori process crescendo laboratori
closur restructur intern busi manag believ counsyl acquisit also
help save program drive effici
deploy myriad plan use excess cash repay debt engag strateg acquisit opportunist
repurchas share addit evalu hurdl rate return capit potenti acquisit manag
look asset would fit strateg myriad portfolio allow better leverag exist
sum myriad leverag strong balanc sheet cash flow gener diversifi away hereditari
cancer businessgiven difficulti bring test market need build sizabl commerci infrastructur
drive adopt expect myriad continu remain consolid space current product line
given myriad alreadi built commerci infrastructur product portfolio increment coverag
drive leverag earn line biggest needl mover genesight manag estim full
reimburs myriad test fiscal year includ counsyl could add million revenu
million free cash flow adjust ep coverag decis may driven either guidelin
expans addit clinic data
attend compani doug vanoort ceo bonello vice presid strategi corpor develop
manag highlight compani larg comprehens multimod test menu uniqu
assay competit advantag addit compani nation footprint extens payer contract well
outstand client servic partnership model help establish leader immuno-
allianc recent announc strateg allianc pharmaceut product develop
repres signific opportun acceler growth pharma cro busi manag
indic allianc could result million annual revenu import long-term
strateg implic facilit compani expans asia provid compani
opportun pursu companion diagnost opportun futur
pma approv one compani on-going initi seek single-sit pma approv fda larg
multigen next-gener sequenc test fda approv may improv compani competit
posit manag expect lead improv reimburs futur base word
final ncd foundat medicin foundationon cdx fda approv would mean next-
gener sequenc test would cover pan-canc assay
pharma pharma servic segment continu gain traction manag present data highlight
growth backlog prior year first quarter pharma revenu million repres
growth compani record million new book end first quarter pharma servic
backlog million expect see sustain acceler pharma servic revenu backlog base
compani strateg allianc discuss
model chang fine-tun estim second quarter reflect season estim
second-quart revenu million versu prior million estim adjust ebitda
million versu prior million estim within adjust estim second-quart
clinic test revenu million versu prior million estim pharma servic revenu
million versu prior million estim slightli increas estim third fourth
quarter estim total revenu adjust ebitda remain
attend compani mark guinan execut vice presid cfo shawn bevec vice presid
unitedhealthcare/aetna regard financi impact recent unitedhealthcar aetna contract renew
number move piec make difficult determin exactli impact quest top
bottom line howev unitedhealthcar contract substanti volum tailwind add million
live compani network case labcorp number potenti benefit
contract renew addit increas volum somewhat off-set lower price
out-of-network busi unit shift in-network includ value-bas price potenti market share
gain region lab manag provid guidanc estim contract chang
increas adjust ep
hospit partnership independ contract chang continu believ quest benefit secular
tailwind manag estim market outsid hospit roughli billion littl
half current serv independ lab given implement pama earli larg independ
lab continu benefit hospit need lower cost rais capit view earli phase
shift market share hospit lab independ lab whether acquisit outreach lab joint
ventur partnership structur lab manag arrang manag state
sizabl opportun consolid market like grow next coupl year
consumer-driven healthcar consum engag continu key focu manag compani
myquest app million user compani also continu invest retail strategi focus
ad patient center safeway locat joint ventur could possibl expand
beyond phlebotomi manag discuss provid addit healthcar
servic opportun expand joint ventur substanti roughli
locat target manag comparison compani current retail site
generation/capit deploy recent discuss dust settl upgrad
outperform continu encourag quest abil gener free cash flow estim free cash flow
million million respect per share basi estim free cash
flow given substanti cash flow gener upsid estim share
buyback therefor adjust ep move expect quest buy back approxim
million million share respect
attend compani bonni anderson ceo keith kennedi cfo
afirma afirma franchis continu gain traction volum grow annual approxim
custom transit genom express classifi gec next-gener genom
sequenc classifi gsc addit compani launch afirma xpression atla may
complement gsc provid addit data rna fusion mutat help guid treatment
decis target therapi basi recent announc collabor loxo oncolog
machin learn platform compani machin learn platform wealth data process
sampl date continu underappreci compon stori high level recent
agreement loxo oncolog compani provid loxo inform regard thyroid cancer
gener afirma xpression atla platform support view biopharma compani becom
increasingli interest leverag biomark move forward see opportun leverag
uniqu thyroid cancer analysi platform databas addit pharma partner eventu may even
opportun monet pharma manag hope extend afirma xpression atla
includ lung cancer idiopath pulmonari fibrosi ipf
lung franchis develop lung franchis highlight percepta test receiv medicar
coverag first coupl quarter follow initi launch encourag volum
ramp slightli faster pace saw launch afirma manag expect continu
gain signific traction percepta larg driven invest compani multiproduct sale team
current guidanc percepta contribut top-lin growth look exit year run-rat
report percepta test per quarter also within lung build data suggest
compani envisia test ipf track obtain medicar coverag collect compani three
product afirma percepta envisia address market expect grow billion
billion
reimburs track record reimburs successan area compani competitor
struggl strong clinic evid portfolio driven guidelin inclus turn driven
coverag decis afirma avail in-network nation unit state nation
coverag determin ncd percepta catalyst includ coverag decis larg
payer scientif advanc field injuri technolog percepta medicar coverag public
clinic valid data envisia
thousand except per share data
good sold
ebit loss oper
adjust gaap net incom
gaap net incom avail common sharehold
gaap net incom prefer share
percent revenu
incom loss oper
tax ebit
tax ebt
incom loss oper
william blair affili manag co-manag public offer equiti secur invita corpor within prior
william blair affili benefici control either directli manag account equiti secur
inc end month end day date herein
william blair affili market maker secur foundat medicin inc invita corpor laboratori corpor
america hold inc inc quest diagnost incorpor inc
william blair affili expect receiv intend seek compens invest bank servic foundat medicin
inc invita corpor laboratori corpor america hold inc inc
incorpor inc affili within next three month
william blair affili receiv compens invest bank servic non-investment-bank servic
corpor within last month invita corpor within last month invest bank client william blair
 compani and/or one affili
offic employe william blair affili research analyst may financi interest secur
foundat medicin inc invita corpor laboratori corpor america hold inc inc quest
diagnost incorpor inc
report avail electron form regist user via doc http //williamblairlibrari bluematrix com
pleas contact us consult williamblair com/research-and-insights/equity-research/coverag aspx disclosur
